A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

NCT00032396 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2006-05-29

No results posted yet for this study

Summary

A study evaluating Retisert in patients with age-related macular degeneration

Conditions

  • Macular Degeneration

Interventions

DRUG

Retisert Implant

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY
  • Control Delivery Systems

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00032396 on ClinicalTrials.gov